Business
Illumina advances preventive genomics through strategic consortium with Veritas Genetics
New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven
About this update from Illumina, Inc.
[{"type":"text","content":"New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven preventionSAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization.\nBuilt around a shared vision for data-driven precision medicine, the collaboration aims to integrate whole-genome sequencing into proactive healthcare. It will empower individuals to proactively leverage whole-genome data to support earlier identification of disease risk, more personalized prevention strategies, and improved long-term health outcomes.\"Genomics is increasingly moving upstream in healthcare, from diagnosing disease to helping prevent it,\" said Rami Mehio, general manager, BioInsight at Illumina. \"By combining Illumina's sequencing and informatics backbone with Veritas' patient-ready reporting, this collaboration represents an important step forward in making preventive genomics actionable, accessible, and integrated into everyday healthcare.\"\"The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer's environment and enable members to benefit from preventive genomics at a personalized level,\" said Javier de EchevarrÃa, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.The consortium is designed to provide:An opt-in preventive genomics program that delivers actionable genomic insights and connects those insights to appropriate interventions.Integrated care pathways for actionable findings, including confirmatory testing, specialist referral where appropriate, guideline-aligned screening, and prevention programs.A streamlined member experience supported by simple sample collection, clear education and consent, results delivery, and access to genetic counseling.A consented, integrated clin...